Presentation by ECDC acting director Dr Andrea Ammon on Human campylobacteriosis in the European Union

1. Dr Andrea Ammon, Acting Director
ECDC, European Centre for Disease Prevention and Control
EP ENVI committee meeting, 15 September 2015
Exchange of views with the European Commission, EFSA and ECDC
Human campylobacteriosis
in the European Union

2. Campylobacter infection in humans –
clinical picture and outcomes
2
Infection
Asymptomatic
Diarrhoea
fever
duration 2-5 days
(10 days)
Reactive arthritis
Guillain-Barré
Syndrome
Death
Recovery

3. Trend in human campylobacteriosis cases
in the EU/EEA, 2008-2014*
• Campylobacter human infections: over 200 000 cases reported annually
• In 2013, about 43% of cases hospitalized (N=27 357)
• In 2013, 56 deaths recorded
• Statistically increasing trend in 2008-2014 (10% increase in 2014)
*Data for 2014 unpublished 3

4. Trend of campylobacteriosis cases by age group
in the EU/EEA, 2008-2014, preliminary data*
*The European Surveillance System, TESSy, ECDC 4

5. Campylobacteriosis burden assessment
5
Under-estimation
0.83 infections/person/year
420 000 000/year in EU
476/100 000
2 400 000/year
66/100 000
220 000/year
Reported
cases
All infections
(symptomatic and
asymptomatic)
Symptomatic
infections
Health care

6. Antimicrobial resistance in
Campylobacter isolates
0%
10%
20%
30%
40%
50%
60%
70%
80%
C. jejuni C. coli
Resistance to ciprofloxacin
Human Broiler Cattle Pigs
6
Low multi-drug resistance and co-resistance to critically important
antimicrobials

7. Summary of campylobacteriosis in EU
• Increasing trend
• Over 200 000 cases reported annually
• Estimated 2,4 million cases annually
• Estimated over 420 million infections annually
• High resistance levels to fluoroquinolones (ciprofloxacin)
• Low multidrug and co-resistance to critically important
antimicrobials
• ECDC activities:
• Study on association with use of antacids
• Close collaboration with EFSA => joint reports
• Successful control needs a holistic approach: One Health!
7